Metreleptin Needs Tighter Partial Lipodystrophy Indication, Panel Says
Executive Summary
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee recommended approval of the Bristol/AstraZeneca drug to treat generalized lipodystrophy but rejected the proposed partial lipodystrophy indication as too broad.